Welcome to our dedicated page for Rxsight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RxSight, Inc. (RXST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. RxSight is an ophthalmic medical device company focused on its Light Adjustable Lens system for cataract surgery patients, and its filings offer detailed insight into how this business is developing.
RxSight uses current reports on Form 8-K to announce material events. Recent 8-K filings have covered topics such as quarterly and interim financial results, including revenue composition between Light Adjustable Lenses and Light Delivery Devices, and leadership changes involving the Chief Financial Officer and Board of Directors. These filings often reference accompanying press releases that provide additional context on procedure volumes, installed base metrics for Light Delivery Devices, and guidance ranges.
Other SEC reports, such as quarterly and annual filings (Forms 10-Q and 10-K), typically include more extensive information on RxSight’s single reportable segment, which encompasses research and development, manufacturing, and sale of Light Adjustable Lenses and related capital equipment. They also describe operating expenses, cash and investment balances, and non-GAAP measures like adjusted net earnings (loss) that exclude stock-based compensation.
On this page, Stock Titan surfaces RxSight’s SEC filings in real time as they become available from EDGAR and pairs them with AI-powered summaries. These summaries are designed to highlight key points—such as changes in operating performance, governance updates, or material agreements—so readers can quickly understand the significance of each document without reading every line.
Investors, analysts, and other interested readers can use this RXST filings page to review Forms 8-K, 10-Q, 10-K, and related exhibits, as well as to monitor ongoing disclosures about RxSight’s Light Adjustable Lens business, financial condition, and corporate governance.
RxSight Inc disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group no longer beneficially owns those securities. The filing states amount beneficially owned: 0 shares representing 0% of the class.
The amendment explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Ashley Grim, Head of Global Fund Administration.
RxSight, Inc. filed an amended report to update details about the compensation of its new Chief Financial Officer, Mark Wilterding. The company confirms that, under his employment agreement effective January 11, 2026, his cash sign-on bonus was set at $169,348.10 and paid on March 13, 2026, after payroll deductions and required withholding.
The amendment also corrects the vesting schedule for his stock option. 25% of the shares underlying the option will vest on the first anniversary of January 11, 2026, and the remaining shares will vest in equal monthly installments over the following three years, so that all option shares are fully vested four years from that date, subject to his continued employment and the terms of the option agreement. All other aspects of the original report remain unchanged.
RxSight, Inc. Chief Financial Officer Mark Wilterding reported equity award activity involving restricted stock units and related common stock. On February 28, 2026, 20,441 restricted stock units were exercised into 20,441 shares of common stock at a price of $0.00 per share. To cover tax obligations on this vesting event, 8,068 shares of common stock were disposed of at $7.61 per share through a tax-withholding arrangement rather than an open-market sale. Footnotes state that one eighth of the RSU award vested on February 28, 2026, with additional one-eighth installments scheduled to vest every six months through the end of a four-year period, subject to continued service.
RxSight, Inc. Chief Customer Officer Scott Gaines reported multiple equity transactions. On February 27, 2026, he received a grant of 32,218 restricted stock units (RSUs), each representing one share of common stock, subject to multi‑year service-based vesting. On February 28, 2026, several RSU awards vested and were exercised, resulting in the acquisition of 6,261 shares of common stock at a stated price of $0.00 per share. On the same date, 2,580 shares of common stock were disposed of at $7.61 per share to cover tax withholding obligations. After these transactions, Gaines directly owned 14,848 shares of RxSight common stock.
Goldshleger Ilya reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. reported that Chief Operating Officer Ilya Goldshleger received a grant of 32,218 restricted stock units on February 27, 2026. Each RSU represents a right to one share of common stock. The award vests in six equal installments on trading days on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029, if he continues as a service provider.
Weinberg Eric reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. reported that officer Eric Weinberg received a grant of 32,218 restricted stock units (RSUs), each representing the right to receive one share of common stock. The award vests in six equal installments on trading days on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029, subject to his continued service.
Kurtz Ronald M MD reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. President & CEO Ronald M. Kurtz received a grant of 80,545 restricted stock units. Each RSU represents a contingent right to receive one share of RxSight common stock.
The award vests in six equal installments, with one-sixth vesting on the first trading day on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029, as long as he continues as a service provider under the company’s 2021 Equity Incentive Plan.
RxSight, Inc. files Post-Effective Amendment converting its shelf registration to a non-automatic Form S-3 and registers up to $200,000,000 of securities. The amendment converts the registration from a Form S-3ASR to a Form S-3 and updates the shelf to permit offers of common stock, preferred stock, debt securities, warrants and units.
This prospectus is a shelf disclosure providing a general description of the securities and states that specific terms, offering sizes, prices and distribution arrangements will be provided in prospectus supplements; sales may occur from time to time after effectiveness.
RxSight, Inc. is a commercial-stage medical technology company focused on premium cataract surgery through its proprietary RxSight Light Adjustable Lens system, which lets surgeons customize a patient’s vision after cataract surgery using ultraviolet light adjustments.
The system combines the Light Adjustable Lens with an office-based Light Delivery Device and has been designed to address key limitations of non-adjustable premium intraocular lenses, such as preoperative guesswork and limited ability to correct residual refractive error. As of December 31, 2025, RxSight had an installed base of 1,134 Light Delivery Devices and surgeons had implanted approximately 300,000 Light Adjustable Lenses since inception.
Management highlights a large and growing opportunity: about 5.2 million cataract surgeries in the U.S. in 2025 and an estimated $860 million U.S. premium IOL market, projected to grow at an 11% CAGR through 2030. The company emphasizes strong clinical data, including higher rates of 20/20 uncorrected vision versus leading toric lenses, and reports research and development expenses of $38.5 million in 2025 as it continues to enhance the system and expand indications. RxSight states it believes its current cash, cash equivalents and short-term investments will fund operations for at least the next 12 months and does not anticipate needing to raise additional capital or incur additional debt to reach profitability from operations, while noting it may opportunistically raise capital to support expansion.
RxSight, Inc. reported mixed fourth quarter and full-year 2025 results, highlighted by strong adoption of its Light Adjustable Lens (LAL) but weaker Light Delivery Device (LDD) sales. Full-year revenue was $134.5 million, down 4% from 2024, as 12% LAL growth was offset by a 48% drop in LDD system sales.
Gross profit for 2025 rose to $103.0 million, with margin improving to 76.6% from 70.7%, driven by a higher mix of LAL revenue. Operating expenses increased 11% to $151.2 million, reflecting commercial expansion, R&D and marketing, leading to a wider net loss of $38.9 million, or $(0.95) per share. Adjusted net loss was $7.3 million, or $(0.18) per share.
In Q4 2025, revenue was $32.6 million, down 19% year over year, with LAL revenue down 1% and LDD revenue down 72% after record placements in the prior year quarter. Q4 gross margin improved to 77.5%, while net loss was $9.2 million. The company ended 2025 with $228.1 million in cash, cash equivalents and short-term investments and an installed base of 1,134 LDDs supporting 109,615 LAL units sold in 2025.
For 2026, RxSight guided to revenue of $120.0–$135.0 million, gross margin of 70%–72%, operating expenses of $150.0–$160.0 million, and non-cash stock-based compensation of $30.0–$32.0 million, reflecting expectations for lower LDD placements and higher per-unit manufacturing costs.